Difference between revisions of "Part:BBa K4165196"
(→‎Dry lab)
Line 14: Line 14:
 
===Dry lab===
 
===Dry lab===
 
<p style=" font-weight: bold; font-size:14px;"> Modeling </p>
 
<p style=" font-weight: bold; font-size:14px;"> Modeling </p>
−
Due to the nonavailability of a model to this peptide we modeled it in our used modeling software's and after the Running of the quality assessment, the models have been scored to get the top model.
+
The peptide was modeled by several software (Alphafold-Apptest-Pepfold) and the best model from Apptest.
−
 
+
 
<html>
 
<html>
 
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/ab-35-42-model.png" style="margin-left:200px;" alt="" width="500" /></p>
 
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/ab-35-42-model.png" style="margin-left:200px;" alt="" width="500" /></p>
Line 21: Line 20:
  
 
                                   Figure 1.: Amyloid-beta (35-42) top model visualized by Pymol.
 
                                   Figure 1.: Amyloid-beta (35-42) top model visualized by Pymol.
−
 
  
 
===References===
 
===References===

Revision as of 19:59, 11 October 2022


Amyloid beta peptide 16 (Aβ 35-42)

This part encodes a part of the Amyloid 𝛽 fragment (35-42) which has the ability to bind to A𝛽 plaques inside the brain.

Usage and Biology

Segments of amyloid beta fibrils are widely used as a recognition sequence for amyloid beta plaques inside the brain, this is due to the homotypic interactions in the C-terminus of fibrils. This peptide starts from amino acid 29 to 42 of the fibril. This binding peptide starts from amino acid 35 to 42.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


Dry lab

Modeling

The peptide was modeled by several software (Alphafold-Apptest-Pepfold) and the best model from Apptest. 

                                 Figure 1.: Amyloid-beta (35-42) top model visualized by Pymol.

References

1-Zhao, Y., Cai, J., Liu, Z., Li, Y., Zheng, C., Zheng, Y., ... & Liu, Y. (2018). Nanocomposites inhibit the formation, mitigate the neurotoxicity, and facilitate the removal of β-amyloid aggregates in Alzheimer’s disease mice. Nano letters, 19(2), 674-683.